**Initial results:** Doses measured by TLD were on average by 4% lower than doses precalculated using the modified algorithm. Mean doses normalized to those pre-calculated and their standard deviations (both in per cents) were respectively: 96.1% and 0.4 % for phantom with diameter of 20; 96.5% and 0.7% for diameter of 30 cm and 96.0% and 0.8% for diameter of 40 cm.

**Conclusions:** Measured doses proved correctness of elaborated algorithm. Very low standard deviations are resulting from regular cylindrical shape of the phantoms.

## 60.

FACTORS DETERMINING LOCAL CONTROL IN PATIENTS (Pts) WITH LOCALLY ADVANCED BREAST CANCER (Labc) MANAGED WITH RADIOTHERAPY (Rt) AS THE PRIMARY LOCOREGIONAL TREAT-MENT

<u>W. Rogowski<sup>1</sup></u>, R. Dziadziuszko<sup>1</sup>, J. Madrzak<sup>1</sup>, M. Welnicka-Jaskiewicz<sup>1</sup>, Peter Barrett-Lee<sup>2</sup>, J. Jassem<sup>1</sup>

<sup>1</sup>Medical University of Gdansk, Poland, <sup>2</sup>Velindre NHS Trust, Cardiff, UK

**Introduction:** RT plays an important role in the management of LABC, yet clinical outcomes still remain far from satisfactory. The aim of this study was to evaluate retrospectively factors determining local control in a large series of consecutive LABC pts managed with RT as the primary locoregional treatment.

Material and methods: The records of 261 primarily inoperable LABC pts treated between 1991 and 1997 at two institutions: Medical University of Gdansk, Poland and Velindre NHS Trust, Cardiff, UK were analysed. All pts received megavoltage RT to the breast with two tangential fields, and the adjacent lymph node areas were irradiated using customised fields. Due to a large scale of RT doses and fractionation schedules, normalised total dose (NTD) was calculated for all patients using a linear guadratic model. In 241 pts RT constituted the only local treatment and the remaining 20 were subsequently subjected pts to mastectomy. Most pts received chemotherapy and/or endocrine therapy prior or after RT.

**Results:** Within the median follow-up of 37 months, locoregional recurrence occurred in 95 of 251 evaluable pts (38%). Three-year and five-year locoregional-free survival rates were 59%

and 48%, respectively. At multivariate analysis of variables predicting the risk of locoregional relapse, inflammatory carcinoma (p<0.01; RR 2.1), T4 disease (p<0.01; RR 2.9) and involvement of supraclavicular lymph nodes (p<0.01; RR 2.4) were the most significant clinical factors, whereas response to RT (p<0.01; RR 1.2) and NTD (p<0.01; RR 0.7) were the most important therapeutic factors. Increasing the total dose to the tumour by 10 Gy was associated with 30% reduction of local relapse.

**Conclusions:** Due to large heterogeneity of LABC pts, judicious tailoring of RT, particularly in terms of dose prescribing, is essential to increase the chance of locoregional cure.

## 61.

THE OUTCOMES OF THE CONVEN-TIONALLY FRACTIONATED RADIO-THERAPY IN THE PROSPECTIIVE AND RETROSPRCTIVE STUDIES. IS THE MEANING OF CONVEN-TIONALITY THE SAME?

## A.Hliniak, W. Michalski, Z. Szutkowski, E. Kraszewska, A. Jarząbski

Centrum Onkologii, Warszawa, Polska

Aim: to discuss some problems of the "conventionality" in the prospective and retrospective studies finished last year at the RT Department in Warsaw. The phase III clinical trial. The study was conducted according to the evidence based rules. Cancer of the larynx glottis and supraglottis T1 - T3 N0 M0 WHO 0 -1, 395 cases 196 in experimental, 199 in conventional arm. The retrospective study concerned all patients with the cancer of larynx treated radically in the II department in years 1989 to May 1995. 372 patients T1- T4, N1-N3, M0. The prospective material 150 patients were selected [age 75 and less, WHO 0-1, T1-T3, N0, M0] employing the same selection criteria as in the prospective study. The comparison was performed with the conventional arm of the clinical trial [199 cases].

**Results of the study:** Significant differences were recorded in the: ? performance status and in the number of T1 and T3 cases, ? compliance to protocol in the total dose and the overall treatment time, ? response to treatment in the whole group and in the particular stages These results indicate the very demanding selection of cases and much more rigorous compliance with the therapeutic protocol in the prospective study.